JP2005512995A - 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト - Google Patents
不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト Download PDFInfo
- Publication number
- JP2005512995A JP2005512995A JP2003541815A JP2003541815A JP2005512995A JP 2005512995 A JP2005512995 A JP 2005512995A JP 2003541815 A JP2003541815 A JP 2003541815A JP 2003541815 A JP2003541815 A JP 2003541815A JP 2005512995 A JP2005512995 A JP 2005512995A
- Authority
- JP
- Japan
- Prior art keywords
- tolterodine
- antimuscarinic agent
- overactive bladder
- effective amount
- antimuscarinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010020853 Hypertonic bladder Diseases 0.000 title claims abstract description 38
- 229940011871 estrogen Drugs 0.000 title claims abstract description 27
- 239000000262 estrogen Substances 0.000 title claims abstract description 27
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title claims abstract description 25
- 208000020629 overactive bladder Diseases 0.000 title claims abstract description 24
- 239000000556 agonist Substances 0.000 title claims abstract description 14
- 230000001022 anti-muscarinic effect Effects 0.000 title 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical group C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims abstract description 53
- 229960004045 tolterodine Drugs 0.000 claims abstract description 52
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000003149 muscarinic antagonist Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000009472 formulation Methods 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 238000013270 controlled release Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 229960005434 oxybutynin Drugs 0.000 description 9
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 206010046494 urge incontinence Diseases 0.000 description 5
- -1 fesoterokine Chemical compound 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 229940108469 vagifem Drugs 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 3
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- DMEPDNFRHUGNPT-UHFFFAOYSA-N [5-(diethylamino)-2-methylpent-3-yn-2-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)C#CCN(CC)CC)C1CCCCC1 DMEPDNFRHUGNPT-UHFFFAOYSA-N 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 2
- 229960002777 dicycloverine Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 229960003210 hyoscyamine Drugs 0.000 description 2
- 229930005342 hyoscyamine Natural products 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 229950000334 temiverine Drugs 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 1
- DUXZAXCGJSBGDW-FQEVSTJZSA-N 2-[(1s)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenol Chemical compound C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-FQEVSTJZSA-N 0.000 description 1
- OOGJQPCLVADCPB-FQEVSTJZSA-N 2-[(1s)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-FQEVSTJZSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010053236 Mixed incontinence Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229960003855 solifenacin Drugs 0.000 description 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001491 trospium Drugs 0.000 description 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34450701P | 2001-11-09 | 2001-11-09 | |
| PCT/SE2002/002041 WO2003039524A1 (en) | 2001-11-09 | 2002-11-07 | Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512995A true JP2005512995A (ja) | 2005-05-12 |
| JP2005512995A5 JP2005512995A5 (enExample) | 2005-12-22 |
Family
ID=23350815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541815A Withdrawn JP2005512995A (ja) | 2001-11-09 | 2002-11-07 | 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト |
| JP2003541844A Pending JP2005514345A (ja) | 2001-11-09 | 2002-11-12 | 更年期以降の女性生殖機能障害の治療のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541844A Pending JP2005514345A (ja) | 2001-11-09 | 2002-11-12 | 更年期以降の女性生殖機能障害の治療のための組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20030118633A1 (enExample) |
| EP (2) | EP1441707A1 (enExample) |
| JP (2) | JP2005512995A (enExample) |
| CA (2) | CA2466336A1 (enExample) |
| MX (2) | MXPA04003866A (enExample) |
| WO (2) | WO2003039524A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518783A (ja) * | 2008-04-09 | 2011-06-30 | コンサート ファーマシューティカルズ インコーポレイテッド | ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法 |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002366800B2 (en) | 2001-12-20 | 2006-08-03 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
| AU2003287248A1 (en) * | 2002-11-12 | 2004-06-03 | Pharmacia And Upjohn Company | Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, an estrogen and an antimuscarinic |
| US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| CA2511995C (en) | 2003-01-02 | 2012-03-13 | Femmepharma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| US20060040904A1 (en) * | 2004-08-17 | 2006-02-23 | Ahmed Salah U | Vaginal cream compositions, kits thereof and methods of using thereof |
| EP1792629A4 (en) * | 2004-08-25 | 2010-08-25 | Takeda Pharmaceutical | MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS |
| WO2006127057A1 (en) * | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
| WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| ES2691646T3 (es) | 2005-07-15 | 2018-11-28 | Micell Technologies, Inc. | Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada |
| EP1971325A2 (en) * | 2005-12-27 | 2008-09-24 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
| AU2007243268B2 (en) | 2006-04-26 | 2013-06-13 | Micell Technologies, Inc. | Coatings containing multiple drugs |
| BRPI0712103A2 (pt) | 2006-05-22 | 2012-01-17 | Hormos Medical Corp | método de tratamento de prostatite não bacteriana crÈnica e para impedir a progressão de hiperplasia prostática benigna (bph) ou cáncer de próstata nos homens |
| WO2007143607A2 (en) | 2006-06-02 | 2007-12-13 | Pear Tree Women's Health Care | Method of treating atrophic vaginitis |
| JP5336382B2 (ja) | 2006-10-23 | 2013-11-06 | ミセル テクノロジーズ、インコーポレイテッド | コーティングの間に基板を荷電するためのホルダー |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| WO2008086369A1 (en) | 2007-01-08 | 2008-07-17 | Micell Technologies, Inc. | Stents having biodegradable layers |
| US20080181932A1 (en) * | 2007-01-30 | 2008-07-31 | Drugtech Corporation | Compositions for oral delivery of pharmaceuticals |
| JP2010527746A (ja) | 2007-05-25 | 2010-08-19 | ミセル テクノロジーズ、インコーポレイテッド | メディカルデバイスコーティング用ポリマーフィルム |
| EP2175843B1 (en) | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| EP2271294B1 (en) | 2008-04-17 | 2018-03-28 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
| GR1006406B (el) * | 2008-05-06 | 2009-05-26 | Specifar Abee ���������� ������� ��� ������������� ��������� | Μικροδισκια παρατεταμενης αποδεσμευσης της τρυγικης τολτεροδινης |
| CA2946195A1 (en) | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
| US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
| US20100239635A1 (en) | 2009-03-23 | 2010-09-23 | Micell Technologies, Inc. | Drug delivery medical device |
| CN102481195B (zh) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | 涂覆支架 |
| WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
| US20110003000A1 (en) * | 2009-07-06 | 2011-01-06 | Femmepharma Holding Company, Inc. | Transvaginal Delivery of Drugs |
| EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
| US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
| US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
| CA2797110C (en) | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
| CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| ES2713523T3 (es) * | 2012-07-18 | 2019-05-22 | Georges Debled | Composición farmacéutica de mesterolona para deficiencias de dihidrotestosterona en la mujer |
| US20140045806A1 (en) * | 2012-07-25 | 2014-02-13 | Fernand Labrie | Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy |
| AU2014248508B2 (en) | 2013-03-12 | 2018-11-08 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
| KR20180059584A (ko) | 2013-05-15 | 2018-06-04 | 미셀 테크놀로지즈, 인코포레이티드 | 생흡수성 생체의학적 임플란트 |
| AU2014349132A1 (en) * | 2013-10-22 | 2016-04-14 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositons and methods |
| WO2018093369A1 (en) * | 2016-11-17 | 2018-05-24 | Goren Ofer A | Treatment of sexual dysfunction and for improved sexual quality of life |
| CN117956979A (zh) * | 2021-09-10 | 2024-04-30 | 斯塔特拉制药股份有限公司 | 局部递送生长和修复促进化合物以治疗、减少和/或预防压力性尿失禁和大便失禁 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US262115A (en) * | 1882-08-01 | Moeeis pollak | ||
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| SE9203318D0 (sv) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| US6310103B1 (en) * | 1996-07-19 | 2001-10-30 | Bridge Pharma, Inc. | S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| SE9701144D0 (sv) * | 1997-03-27 | 1997-03-27 | Pharmacia & Upjohn Ab | Novel compounds, their use and preparation |
| MY127946A (en) * | 1998-08-27 | 2007-01-31 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
| HK1048269B (zh) * | 1999-06-11 | 2006-01-13 | 沃特森药物公司 | 非口服雄激素类固醇用於制备改善性激素结合球蛋白水平升高的药物 |
| MXPA03006597A (es) * | 2001-03-28 | 2004-10-15 | Pfizer | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad. |
-
2002
- 2002-11-07 WO PCT/SE2002/002041 patent/WO2003039524A1/en not_active Ceased
- 2002-11-07 US US10/289,903 patent/US20030118633A1/en not_active Abandoned
- 2002-11-07 MX MXPA04003866A patent/MXPA04003866A/es not_active Application Discontinuation
- 2002-11-07 JP JP2003541815A patent/JP2005512995A/ja not_active Withdrawn
- 2002-11-07 EP EP02783937A patent/EP1441707A1/en not_active Withdrawn
- 2002-11-07 CA CA002466336A patent/CA2466336A1/en not_active Abandoned
- 2002-11-12 EP EP02789581A patent/EP1443939A1/en not_active Withdrawn
- 2002-11-12 JP JP2003541844A patent/JP2005514345A/ja active Pending
- 2002-11-12 US US10/292,742 patent/US20030130244A1/en not_active Abandoned
- 2002-11-12 WO PCT/US2002/036167 patent/WO2003039553A1/en not_active Ceased
- 2002-11-12 MX MXPA04004364A patent/MXPA04004364A/es unknown
- 2002-11-12 CA CA002464707A patent/CA2464707A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518783A (ja) * | 2008-04-09 | 2011-06-30 | コンサート ファーマシューティカルズ インコーポレイテッド | ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005514345A (ja) | 2005-05-19 |
| US20030118633A1 (en) | 2003-06-26 |
| MXPA04004364A (es) | 2004-08-11 |
| WO2003039553B1 (en) | 2004-07-08 |
| MXPA04003866A (es) | 2004-07-08 |
| EP1441707A1 (en) | 2004-08-04 |
| WO2003039524A1 (en) | 2003-05-15 |
| EP1443939A1 (en) | 2004-08-11 |
| US20030130244A1 (en) | 2003-07-10 |
| CA2464707A1 (en) | 2003-05-09 |
| CA2466336A1 (en) | 2003-05-15 |
| WO2003039553A1 (en) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512995A (ja) | 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト | |
| CN1199621C (zh) | 治疗痛经的装置和药物 | |
| TWI222879B (en) | Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder | |
| JPH01221318A (ja) | ダナゾール含有の局所投与製剤 | |
| MD3518933T4 (ro) | Metode de tratare a fibromului uterin și a endometriozei | |
| TW200831107A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| CA2471400A1 (en) | Vaginal delivery of drugs | |
| US20020161352A1 (en) | Vaginal ring preparation and application | |
| EP2037927A1 (en) | Flibanserin for the treatment of urinary incontinence and related diseases | |
| US20060058777A1 (en) | Urinary catheter device with a pharmaceutically active composition | |
| AU6891100A (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| JP2002505280A (ja) | 一過性熱感を軽減するための塩酸フルオキセチン | |
| US20050197651A1 (en) | Vaginal ring preparation and its application | |
| KR20000048981A (ko) | 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진 호르몬 조성물 | |
| TW200307553A (en) | Treatment of post-menopausal complaints in breast cancer patients | |
| TW201832767A (zh) | 治療婦科疾病之組合物 | |
| JP2004529176A (ja) | 頸管熟化を誘導するためのホスホジエステラーゼインヒビターを含む組成物 | |
| CN101309702A (zh) | 使用克罗米酚治疗女性不育症的方法及其组合物 | |
| Bygdeman et al. | Pregnancy termination | |
| US20110003000A1 (en) | Transvaginal Delivery of Drugs | |
| CN116726024A (zh) | 一种治疗良性前列腺增生症的药物及其制备方法 | |
| JP2008523143A (ja) | 月経困難症の治療のためのα−アドレナリン遮断剤の使用 | |
| JP2006515607A (ja) | 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少 | |
| KR100879656B1 (ko) | 긴장성 요실금을 치료하기 위한 국소용 조성물 및 방법 | |
| US12011423B2 (en) | S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060220 |